Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2023-12-18 Major Shareholding Noti…
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
Change in substantial holding 3 pages 165.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, specifically a "Notice of change of interests of substantial holder." It details changes in voting power and relevant interests of a substantial shareholder, Andreas Fouras, in 4DMedical Limited. The form includes dates of changes, nature of changes, and associated parties. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it does not fit other categories such as director dealings or capital changes. Therefore, the correct classification is MRQ.
2023-12-18 English
Change in substantial holding 3 pages 163.3KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 filed under the Corporations Act 2001, specifically a "Notice of change of interests of substantial holder." It details changes in voting power and relevant interests of a substantial shareholder, Helen Fouras, in 4DMedical Limited. The form includes dates of changes, nature of changes, and relevant shareholding percentages. This type of filing is a notification of changes in significant share ownership levels, which aligns with the definition of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure about shareholding changes.
2023-12-18 English
4DMedical completes acquisition of Imbio 2 pages 236.0KB
M&A Activity Classification · 95% confidence The document is an ASX announcement dated 18 December 2023 about 4DMedical completing the acquisition of Imbio, a U.S.-based medical technology company. The content focuses on the acquisition details, strategic benefits, revenue forecasts, and future outlook. There are no financial statements, quarterly or annual report data, or detailed financial analysis. The document is a corporate announcement about a merger/acquisition event rather than a full merger filing or proxy statement. It fits best under the category for M&A Activity announcements, which covers announcements and documents related to merger proposals or takeover bids. The document length is about 5757 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is TAR (M&A Activity).
2023-12-17 English
Cleansing Notice 1 page 175.6KB
Capital/Financing Update Classification · 100% confidence The document is a notification under section 708A(5)(e) of the Corporations Act regarding the issuance of new shares as part of a placement to raise capital. It confirms compliance with disclosure obligations and provides details about the share issuance. The content focuses on capital raising and share issuance rather than financial results, management changes, or other report types. The document length is short (1985 characters) and it is an announcement of a capital raising event, not a full financial report or detailed presentation. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-12-14 English
Application for quotation of securities - 4DX 7 pages 28.6KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Application for quotation of +securities' and details the application for quotation of securities issued by 4DMEDICAL LIMITED. It includes information about the number and type of securities to be quoted, issue dates, and references to previous announcements such as Appendix 3B. The content focuses on the listing and quotation of new securities on the ASX, including details of issued capital following quotation. There is no financial performance data, earnings information, or management discussion. The document is an official announcement related to capital market activities, specifically the quotation of securities, which aligns with announcements about share issues or capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is 5494 characters, which is sufficient to be the announcement itself, not just a report publication announcement or regulatory filing. Confidence is high due to clear and specific content about securities quotation and issuance.
2023-12-13 English
4DMedical acquires Imbio and completes equity raising 8 pages 442.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 11 December 2023 by 4DMedical Limited regarding the acquisition of Imbio, a U.S.-based medical technology company. It details the terms of the acquisition, including purchase price, contingent earnouts, and funding via a capital raising (placement) of A$35 million. The announcement also includes information about the placement offer, shareholder approval requirements, and an investor webinar. The content focuses on the transaction summary, capital raising details, and strategic rationale for the acquisition. There are no financial statements or detailed financial performance data presented, nor is this a transcript, management report, or regulatory filing of a financial report. The document is a formal announcement of a merger and capital raising event. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it covers company fundraising and acquisition financing activities.
2023-12-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.